RxDoctor Payments Data

Joseph Lomboy, MD

Internal Medicine · Perry, GANPI 1215974100

Payments from drug & device makers

$23,309in general payments, 2019–2025

Across 400 payments — averaging $58.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$11K
  • GSK$5K
  • Amgen$797
  • Novo Nordisk$669
  • Pfizer$637
  • Lilly USA, LLC$619
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$7,597100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,309 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$492,905
Medicare patients
465
Services billed
10,903

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$128,972
MounjaroTirzepatide74$87,628
JardianceEmpagliflozin55$79,730
EliquisApixaban51$58,736
FarxigaDapagliflozin Propanediol54$50,295
EntrestoSacubitril/Valsartan13$16,781
LinzessLinaclotide21$16,620
JanuviaSitagliptin Phosphate19$14,945
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$12,964
XareltoRivaroxaban17$12,759
BelsomraSuvorexant20$12,304
Repatha SureclickEvolocumab19$10,627
Praluent PenAlirocumab13$6,760
Megestrol Acetate20$2,858
Levothyroxine Sodium122$2,305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$669$128,972109 claims
Lilly USA, LLCMounjaro$619$87,62874 claims
Boehringer IngelheimJardiance$163$79,73055 claims
PfizerEliquis$637$58,73651 claims
AstraZenecaFarxiga$548$50,29554 claims
MerckJanuvia, Belsomra$123$27,24939 claims
NovartisEntresto$176$16,78113 claims
AbbVieLinzess$379$16,62021 claims
GSKTrelegy Ellipta$5,378$12,96412 claims
Johnson & JohnsonXarelto$135$12,75917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Perry

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →